Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

EFFECT OF SUBCUTANEOUS SEMAGLUTIDE 2.4 MG ONCE-WEEKLY COMPARED TO PLACEBO IN SUBJECTS WITH OBESITY AND KNEE OSTEOARTHRITIS

Intervention/treatment:
TBD (SEMAGLUTIDE S.C.)
Medical condition:
OSTEOARTHRITIS OF THE KNEE
Protocol code:
NN9536-4578
Control number:
243722
Status:
Closed
Approved:
November 18, 2020
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05064735
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
Accepts healthy volunteers: Yes

Contacts and locations

Contact
Name
Clinical Reporting Office (2834)
Organization
Novo Nordisk A/S
Phone:
(+1) 866-867-7178
Sponsor
NOVO NORDISK CANADA INC

Locations

Alberta

C-endo Diab & Endo Clinic
Edmonton, Alberta, T6H 2L4
C-endo Diab Endo Clin Calgery
Calgary, Alberta, T2V 4J2

British Columbia

Ocean West Research Clinic
Surrey, British Columbia, V3Z 2N6

New Brunswick

G.A. Research Associates Ltd.
Moncton, New Brunswick, E1G 1A7

Newfoundland and Labrador

Commonwealth Medical Clinic
Mount Pearl, Newfoundland and Labrador, A1N 1W7

Ontario

Dr Anil K Gupta Med Prof Corp
Toronto, Ontario, M9V 4B4
Institut universitaire de cardiologie
Québec, Ontario, G1V 4G5
Manna Research Inc. (Burlington N)
Burlington, Ontario, L7M 4Y1
Manna Research Inc._Toronto
Toronto, Ontario, M9W 4L6
Master Centre for Canada
Toronto, Ontario, M5V 3L9
Milestone Research
London, Ontario, N5W 6A2
Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, L8M 1K7
Wharton Med Clin Trials
Hamilton, Ontario, L8L 5G8

Quebec

Centre Medical Acadie
Montreal, Quebec, H4N 2W2
CHU de Quebec-Universite Laval
Québec, Quebec, G1J 1Z4
Ctr Méd. et pro d l'Ost d port
Saint-Marc-des-Carrieres, Quebec, G0A 4B0

Results

See the results from the trial NCT05064735. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?